Quisque vel mauris ac
Maecenas eget lacus metus. Pellentesque accumsan faucibus enim
Duis a mauris euismod ex rhoncus tempus. Etiam mi ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Drug discovery scientists often believe gram scale quantities of active pharmaceutical ingredient (API) are required to determine chemistry, manufacturing, and controls (CMC) properties like solubility, oral absorption, salt selection, and formulation strategy. But in this webinar, Crystal Pharmatech Co-Founder and Chief Business Officer, Robert Wenslow will present advanced computational approaches and a focused lab component to provide you with development risks with only 25mg of material. This allows developability to truly mainstream into late lead optimization and significantly enhance the probability of success (POS) for Phase I candidates. Attendees will have the chance to get their questions answered during the live Q&A moderated by Simulations Plus Senior Director, Business Development, Arlene Padron. Don’t miss out on this opportunity to learn from an industry expert—register now.
Thursday, September 11, 2025
8:00 am - 9:00 am PDT
Co-Founder & Chief Business Officer Robert Wenslow is a seasoned drug development scientist with a strong background in pharmaceutical characterization. He has extensive experience in all solid-state research issues relating to the pharmaceutical industry. He and his team at Crystal Pharmatech will work with you to speed up your drug discovery, research, and development needs at a containable cost. 26 years of experience in pharmaceutical development, including 14 years at Merck with various leadership positions. Headed the API group - Center for Materials Science and Engineering in Merck Manufacturing Division. Established the first analytical research group in Ireland for Merck, while also maintaining direct responsibilities for overseeing the solid-state NMR facility. Obtained a Ph.D. degree in Chemistry from Pennsylvania State University Expertise: Solid-state NMR, drug characterization, crystallization development, IP protection; Expert witness on crystal form patent cases
Crystal Pharmatech, Inc.
Director, Business Development
Simulations Plus
Andrew Mueller has approximately 17 years’ experience in the
pharmaceutical development industry.
He joined Simulations Plus in 2020 as a Project Coordinator, Technical Writer, and Coordinator for Learning Services and now serves as a Director for Business Development.
Prior to his employment with Simulations Plus, Andrew spent the majority of his career with Covance Laboratories (LabCorp) in Toxicology, as a Lead Scientist in Bioanalytical Chemistry,
and as a Pharmacokineticist in Drug Metabolism.
Speaker Title 3
Speaker Company 3Enter Text Here
Speaker Title 4
Speaker Company 4Enter Text Here
Speaker Title 5
Speaker Company 5Enter Text Here
Speaker Title 6
Speaker Company 6Enter Text Here
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!